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Introduction {#sec001}
============

Cutaneous leishmaniasis (CL) is a chronic infectious skin disease caused by a group of protozoan parasites of the *Leishmania* genus. The parasites are transmitted to humans via the bite of phlebotomine sandflies and predominantly target reticulo-endothelial cells \[[@pntd.0004495.ref001]\]. CL can present with a spectrum of clinical manifestations. Ulcerative skin lesions occurring at the site of the bite of the sandfly is the most common cutaneous manifestation (localized CL---LCL). While usually healing spontaneously after several months, it remains disfiguring and stigmatizing and often heals with scarring. There are several more rare forms like diffuse CL (DCL), which is often difficult to treat \[[@pntd.0004495.ref001]\]. Mucosal leishmaniasis (ML) or mucocutaneous CL (MCL) refers to an often destructive form with mucosal inflammation, which has been mainly reported in the New World---in association with *L braziliensis* \[[@pntd.0004495.ref001],[@pntd.0004495.ref002]\]---but also in the Old World \[[@pntd.0004495.ref003]\]. At the global level, around one million cases of CL occur annually \[[@pntd.0004495.ref004]\]. In the New World, *L braziliensis* causes the largest CL burden, with Brazil most severely affected. In the Old World, most cases are found in the Middle East, North Africa, the Indian subcontinent and Central Asia \[[@pntd.0004495.ref004]\].

While CL in the Old world is predominantly caused by *L tropica* and *L major*, it is still estimated that several ten thousands of cases are due to *L aethiopica*. These predominantly occur in Ethiopia, and more exceptionally in Kenya. Within Ethiopia, the annual CL burden is estimated at around 20.000 to 40.000 cases per year \[[@pntd.0004495.ref004]\], of which 99% is thought to be due to *L aethiopica* \[[@pntd.0004495.ref005]\]. A recent study estimated almost 30 million of Ethiopians to be at risk for CL \[[@pntd.0004495.ref006]\]. CL in Ethiopia is a zoonotic disease, mainly occurring in the highland regions, involving rock hyraxes as reservoir. The disease predominantly affects children, adolescents and young adults \[[@pntd.0004495.ref007]--[@pntd.0004495.ref010]\]. In the Northern part of Ethiopia, HIV coinfection rates of 5.6% have been reported \[[@pntd.0004495.ref007]\]. An outbreak of CL has recently been described \[[@pntd.0004495.ref011]\].

Clinical manifestations of *L aethiopica* are particularly diverse and pleotropic, and a high genetic diversity has been documented as well \[[@pntd.0004495.ref012]\]. Localized CL (LCL) is the most frequent manifestation, while mucocutaneous (MCL) and diffuse CL (DCL) is relatively common \[[@pntd.0004495.ref007]\]. Compared to LCL, MCL is reportedly less responsive to treatment and is more disfiguring \[[@pntd.0004495.ref001]\]. DCL is notorious for its chronic and progressive course and non-responsiveness to the common antileishmanial drugs. It is characterized by highly parasitized nodular lesions spread throughout the body and the failure to mount an effective antileishmanial immune response. Even if lesion regression can be obtained with chemotherapy, most cases of DCL will relapse after treatment discontinuation \[[@pntd.0004495.ref001]\]. Outside Ethiopia, DCL is rare and occasionally seen linked to *L amazonensis* and *L mexicana* \[[@pntd.0004495.ref001],[@pntd.0004495.ref013]\].

Since its occurrence is restricted to almost a single country with limited resources, research on this species has been relatively limited, especially over the last 10 to 20 years when commitments to combat neglected tropical diseases have been enhanced and major scientific and technological breakthroughs have occurred. In terms of treatment of *L aethiopica*, the evidence base remains extremely limited. A Cochrane review published in 2008 identified not a single randomized clinical trial dedicated to CL in Ethiopia \[[@pntd.0004495.ref014]\]. Nevertheless, *L aethiopica* has particular features (the frequent occurrence of DCL and MCL) that imply a potentially higher need of systemic therapy, as compared to other species such as *L major or L tropica*. It is clear that randomized clinical trials are highly needed and should be undertaken. It is however less clear which interventions should be selected for prioritization in these studies. We conducted a systematic review including any type of clinical study reporting on outcomes in humans of drug treatment of CL due to *L aethiopica*, in order to help identify potentially efficacious medications for CL that can be taken forward in clinical trials. Laboratory studies evaluating drug susceptibility of *L aethiopica* against currently available antileishmanial drugs were reviewed as well.

Methods {#sec002}
=======

Types of studies and search strategy {#sec003}
------------------------------------

This review was conducted in line with the PRISMA guidelines; the PRISMA checklist was completed (See [S1 Checklist](#pntd.0004495.s001){ref-type="supplementary-material"}) \[[@pntd.0004495.ref015]\]. The sources searched and the search terms used are presented in Tables [1](#pntd.0004495.t001){ref-type="table"} and [2](#pntd.0004495.t002){ref-type="table"}. Additional publications were identified by reviewing the reference lists of selected papers and by contacting experts in the field. As a first step, titles and abstracts were reviewed independently by two reviewers (JvG and ED) and those selected by at least one reviewer were included for evaluation of the full text. The final selection of studies to be included for data extraction was done independently by two reviewers (JvG and ED), with discrepancies solved by consensus. The scope of the review was any study in humans reporting on treatment outcomes of CL due to confirmed or presumed *L aethiopica*. There was no selection based on patient age, sample size, study design, language or period. There was no selection by type of intervention (systemic, local, physical or other). Since the aim of this review was to prioritize interventions to be taken forward in phase III clinical trials, early studies on traditional therapies were not considered. No specific criteria were set for the outcome (treatment response), besides that the paper had to include at least some information on evolution after treatment. On some occasions, authors were contacted for additional information or clarifications. No specific protocol was developed for this systematic review.

10.1371/journal.pntd.0004495.t001

###### Search terms and date of first and latest search for the different electronic databases used.

![](pntd.0004495.t001){#pntd.0004495.t001g}

  Source                                                                                          Search terms                                                                             Date of first and latest search[^a^](#t001fn001){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- -----------------------------------------------------------------------
  Pubmed/Medline                                                                                  See [Table 2](#pntd.0004495.t002){ref-type="table"}                                      2013/11/12--2015/09/20
  Cochrane Register of Studies Cochrane Central Register of Controlled Trials (CENTRAL) CENTRAL                                                                                            2015/09/20
  Clinical trial.gov                                                                              Cutaneous leishmaniasis or cutaneous leishmania                                          2013/11/12--2015/09/20
  Google scholar                                                                                  (cutaneous leishmaniasis) (ethiopia OR aethiopica OR ethiopica) (treatment OR therapy)   2013/11/12--2015/09/20

^a^ First date is the date the search started; last date is the date the search was updated

10.1371/journal.pntd.0004495.t002

###### Medline search strategy.
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  Nr          Search terms
  ----------- ---------------------------------------------------------------
  **\#1.**    Leishmaniasis, Cutaneous/complications \[Mesh\]
  **\#2.**    Leishmaniasis, Cutaneous/drug therapy \[Mesh\]
  **\#3.**    Leishmaniasis, Cutaneous/epidemiology \[Mesh\]
  **\#4.**    Leishmaniasis, Cutaneous/therapy \[Mesh\]
  **\#5.**    Leishmaniasis, Cutaneous/surgery \[Mesh\]
  **\#6.**    Leishmaniasis/prevention and control \[Mesh\]
  **\#7.**    1-6/or
  **\#8.**    Ethiopia \[Mesh\]
  **\#9.**    Ethiopica (ALL) OR aethiopica (ALL)
  **\#10.**   8 or 9
  **\#11.**   7 and 9
  **\#12.**   therapy
  **\#13.**   treatment
  **\#14.**   Management
  **\#15.**   therapeutic use
  **\#16.**   drug therapy
  **\#17.**   drug treatment
  **\#18.**   clinical care
  **\#19.**   cryotherapy
  **\#20.**   Cryosurgery
  **\#21.**   12-20/or
  **\#22.**   leishmaniasis or leishmania or (oriental sore)
  **\#23.**   (visceral leishmaniasis) OR Leishmaniasis, visceral \[MESH\])
  **\#24.**   22 and 10
  **\#25.**   24 not 23
  **\#26.**   21 and 25
  **\#27.**   11 or 26

Data extraction and analysis {#sec004}
----------------------------

Data were extracted into pre-piloted tables by one reviewer (JvG) and verified by a second reviewer (ED), with discrepancies solved by consensus. Key outcome data were verified by duplicate extraction. The following information was extracted: 1) patient characteristics: age, sex, duration of lesions, type of CL (LCL, MCL or DCL); 2) whether the diagnosis was parasitologically confirmed and whether species identification was done; 3) travel-related or not; 4) treatment details; 5) treatment response and definitions used; 6) adverse events associated with the intervention; 7) relevant information relating to study quality or interpretation. Based on previously conducted SR on New World CL \[[@pntd.0004495.ref014]\], we anticipated that no or very few (high quality) clinical trials would be found, but rather expected a range of small, generally non-randomized (low quality) studies, all with obvious study limitations. We used the Newcastle-Ottawa Scale (NOS) to assess the quality of nonrandomized studies \[[@pntd.0004495.ref016]\]. Three broad perspectives were assessed: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. Clinical trials were evaluated as per standard quality assessment tool for randomized controlled trials in line with recommendations in the Cochrane handbook \[[@pntd.0004495.ref017]\]. Given the nature of extracted data, only simple descriptive analysis was conducted, summarizing the individual studies.

Results {#sec005}
=======

Characteristics of the selected manuscripts and strengths and weaknesses {#sec006}
------------------------------------------------------------------------

Out of a total of 95 studies or reports identified and screened, only 27 provided information relevant to our topic ([Fig 1](#pntd.0004495.g001){ref-type="fig"}). This comprised 13 case series and seven case reports, generally clinical information collected as part of clinical practice. Most of these were reported over 30 to 40 years ago. There were two more recent prospective observational studies whereby a study protocol had been written and patient consent was requested. Since treatment allocation was based on CL type and/or severity, no true comparison in efficacy could be made. Only two small clinical trials were identified, one on tuberculosis drugs and pentamidine reported in 1981 and a small placebo-controlled trial on itroconazole reported in 1990. Three additional studies yielded relevant drug susceptibility information.

![Overview of records identified, screened, reviewed and included in the review.](pntd.0004495.g001){#pntd.0004495.g001}

In total, outcomes of 506 treatment episodes were reported (excluding one report because of potential overlap). Most commonly used drugs were antimonials (n = 201), pentamidine (n = 150) and cryotherapy (n = 103). The majority of studies reported on patients being treated in *L aethiopica* endemic regions (one in Kenya, the other in Ethiopia) but only three of these studies did species identification in all reported cases. There were three cases of migrants treated in Europe or Israel. We identified nine studies on LCL cases, seven on DCL and two on MCL cases. In addition, three included LCL and DCL cases, two included LCL and MCL and DCL cases and one included LCL, MCL and DCL patients.

Most studies had obvious limitations, beyond the descriptive nature. Definitions of treatment outcomes varied across studies and were often not clearly defined. Sample size was often small, follow-up short and information on patient characteristics often limited. In formal quality assessment, the non-randomized studies performed poorly, with a median score of three (maximum score is eight), see [Table 3](#pntd.0004495.t003){ref-type="table"}. Only the two prospective studies reached a score of five. The oldest clinical trial on tuberculosis drugs and pentamidine had a high risk for blinding of participants/staff and outcome assessment, an unclear risk for bias for random sequence generation, allocation concealment and selective reporting and a low risk for incomplete outcome data. The trial on itraconazole had a low risk for random sequence generation, allocation concealment and blinding of participants/staff and outcome assessment, an unclear risk for bias for selective reporting and a high risk of bias for incomplete outcome data.

10.1371/journal.pntd.0004495.t003

###### Assessment of study quality of non-randomized studies using the Newcastle-Ottawa Scale (NOS).
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                                                      Treatment group representative   Control group representative   Treatment details given   Outcome not pre-existing   Comparability of groups   Independent outcome ascertainment   Follow up time (≥ 3 months)   Loss to follow up (\<10%)   Total score
  --------------------------------------------------- -------------------------------- ------------------------------ ------------------------- -------------------------- ------------------------- ----------------------------------- ----------------------------- --------------------------- -------------
  \[[@pntd.0004495.ref007]\]                          \*                               \*                             \*                        \*                         0                         0                                   \*                            0                           5
  \[[@pntd.0004495.ref046]\]                          \*                               \*                             \*                        \*                         0                         0                                   \*                            0                           5
  \[[@pntd.0004495.ref005]\]                          0                                0                              \*                        \*                         0                         0                                   0                             0                           2
  \[[@pntd.0004495.ref047]\]                          0                                0                              \*                        \*                         0                         0                                   \*                            \*                          4
  \[[@pntd.0004495.ref048]\]                          0                                0                              0                         \*                         0                         0                                   \*                            \*                          3
  \[[@pntd.0004495.ref049]\]                          0                                0                              0                         \*                         0                         0                                   0                             \*                          2
  \[[@pntd.0004495.ref050]\]                          0                                0                              \*                        \*                         0                         0                                   0                             0                           2
  \[[@pntd.0004495.ref051]\]                          0                                0                              0                         \*                         0                         0                                   0                             0                           1
  \[[@pntd.0004495.ref052]\]                          0                                0                              \*                        \*                         0                         0                                   0                             0                           2
  \[[@pntd.0004495.ref053]\]                          0                                0                              \*                        \*                         0                         0                                   0                             0                           2
  \[[@pntd.0004495.ref054]\]                          0                                0                              \*                        \*                         0                         0                                   0                             0                           2
  \[[@pntd.0004495.ref055]\]                          0                                0                              \*                        \*                         0                         0                                   \*                            \*                          4
  \[[@pntd.0004495.ref056]\]                          0                                0                              \*                        \*                         0                         0                                   0                             \*                          3
  \[[@pntd.0004495.ref057]\]                          0                                0                              0                         \*                         0                         0                                   0                             0                           1
  \[[@pntd.0004495.ref058]\]                          0                                0                              \*                        \*                         0                         0                                   \*                            \*                          4
  \[[@pntd.0004495.ref059]\]                          0                                0                              \*                        \*                         0                         0                                   0                             \*                          3
  \[[@pntd.0004495.ref060]\]                          0                                0                              \*                        \*                         0                         0                                   0                             0                           2
  \[[@pntd.0004495.ref061],[@pntd.0004495.ref062]\]   0                                0                              \*                        \*                         0                         0                                   0                             \*                          3
  \[[@pntd.0004495.ref021]\]                          0                                0                              \*                        \*                         0                         0                                   \*                            \*                          4
  \[[@pntd.0004495.ref063]\]                          0                                0                              \*                        \*                         0                         0                                   0                             \*                          3
  \[[@pntd.0004495.ref053]\]                          0                                0                              \*                        \*                         0                         0                                   0                             \*                          3
  \[[@pntd.0004495.ref064]\]                          0                                0                              0                         \*                         0                         0                                   0                             0                           1

Three broad perspectives were assessed: the selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. Stars (\*) indicate higher quality.

Clinical studies on LCL and MCL treatment {#sec007}
-----------------------------------------

We identified a total of 17 clinical studies reporting on treatment of CL or MCL (presumably) due to *L aethiopica*, relating to 384 treatment episodes ([Table 4](#pntd.0004495.t004){ref-type="table"}). There were two small clinical trials, two prospective non-randomized studies and 13 case reports/series. All but two included less than 100 patients. Species identification was systematically done in only six reports. One small placebo-controlled randomized clinical trial (n = 14) evaluated oral itraconazole for LCL and DCL and found it as effective as placebo. In another clinical trial, isoniazid, rifampicin and amithiozone were compared with pentamidine injections. While only one out of six patients improved with the former treatment, all six cases on pentamidine demonstrated improvement. However, no species identification was done and half of the cases were not parasitologically confirmed.

10.1371/journal.pntd.0004495.t004

###### Clinical studies on cutaneous and mucocutaneous leishmaniasis due to *L. aethiopica*.
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  Ref                                                                          Study design; country; year; study population[^a^](#t004fn001){ref-type="table-fn"}   Patient characteristics       Drug/Intervention                N                Efficacy                           Comments
  ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------- -------------------------------- ---------------- ---------------------------------- -----------------------------------------
  **Clinical trials**                                                                                                                                                                                                                                                                   
  \[[@pntd.0004495.ref065]\]                                                   Clinical trial, ALERT                                                                 Each group: 1 single LCL      INH 300 mg, rifampicin           6                Clinically improved: 1 (at         Case that improved
                                                                               Ethiopia; 1981                                                                        histologically diagnosed      600 mg and amithiozone                            8 weeks---EOT)                     was smear(-) at start
                                                                               No species identification                                                             smear(-)/LST(+); 3 multiple   150 mg for at least 8 weeks                                                          (histologically
                                                                                                                                                                     LCL smear(+)/ LST(+);         Pentamidine                      6                All 6 clinically improved          diagnosed)
                                                                                                                                                                     2 multiple LCL smear          dimethansulphonate 4                              and skin smear negative            Treatment allocation
                                                                                                                                                                     pos(+)/LST(-)                 mg/kg 15 doses alternative                        EOT (4 weeks)                      not clear: random?
                                                                                                                                                                     No further details            days IM                                                                              
  \[[@pntd.0004495.ref021]\]                                                   Placebo-controlled                                                                    Age 12--48 years              Itraconazole 4 x 50 mg PO        7                EOT: active lesion 7;              Itraconazole generally
                                                                               randomized double                                                                                                   daily for 4 weeks                                 clinically improved 0              well tolerated
                                                                               blind clinical trial                                                                                                                                                  M1 FU: 2/5 improved                None of the DCL
                                                                               ALERT/AHRI                                                                                                                                                            Parasite culture(-): 2/5           patients improved
                                                                               Ethiopia; 1990                                                                                                      Placebo                          7                EOT: active lesion 5;              Generation of
                                                                               CL (10) and DCL (4)                                                                                                                                                   clinically improved 2              randomization and
                                                                               No species identification                                                                                                                                             M1 FU: 4/7 improved                concealment of
                                                                                                                                                                                                                                                     Parasite culture(-): 4/7           allocation not
                                                                                                                                                                                                                                                                                        clear
  **Main focus antimonials or cryotherapy**                                                                                                                                                                                                                                             
  \[[@pntd.0004495.ref007]\]                                                   Prospective evaluation                                                                75.3% males;                  LCL: SSG local injection         154              6M overall outcome:                13 of 167 not treated
                                                                               in free NGO CL clinic;                                                                Age 5--14: 40 (24%)           every 3 days/4 weeks                              69% (106) cure; 15%                (11 mild; 2 severe CL)
                                                                               Tigray region, Ethiopia                                                               Age 15--44: 113 (68%)         DCL, MCL, RCL, PKDL,                              \(23\) failure; 14% (21)           Cure: free from clinical
                                                                               1/2005-7/2007                                                                                                       relapse: MA 20 mg/kg                              relapse; 4 stopped                 and microbiological
                                                                               No species identification                                                                                           for 30 days IV                                    systemic SSG for                   All cases presumably
                                                                                                                                                                                                                                                     toxicity                           parasitologically
                                                                               LCL (123; 13 not treated)                                                                                                                            110              0 non-response, 9 relapse          confirmed (?)
                                                                               DCL (11)                                                                                                                                             11               8 non-response; 3 relapse          HIV coinfection 5.6%
                                                                               MCL (29)                                                                                                                                             29               13 non-response; 7 relapse         (5/89): all relapsed
                                                                               ML (1)                                                                                                                                               1                1 non-response                     11 of 21 relapses:
                                                                               PKDL (1)                                                                                                                                             1                1 non-response                     no response to
                                                                               RCL (2)                                                                                                                                              2                0 non-response, 2 relapse          prolonged IV SSG
                                                                               DCL; SSG resistant                                                                                                  Pentamidine isothionate          8                7/8 (87% cured) by M6              No intolerance to
                                                                               relapse (1)                                                                                                         (if non response to SSG)                          Cure in MCL and MCL                pentamidine
                                                                               MCL; SSG resistant                                                                                                  4 mg/kg every                                     DCL case initially                 
                                                                               relapse (6)                                                                                                         second day till negative                          clinically improved;               
                                                                               RCL; SSG resistant relapse                                                                                          aspirate + clinical resolution                    followed by relapse                
                                                                               relapse (1)                                                                                                         (\~ 20 days)                                                                         
  \[[@pntd.0004495.ref046]\]                                                   Non-randomized prospective                                                            Mean age 18.4 years           Liquid nitrogen weekly           103              Cure: 83 (80.6%)                   Per protocol cure rate
                                                                               prospective study                                                                     Male 53/103                   until cure (3--4 sessions                         Non-response: 6 (5.8%)             Cryotherapy: 93.3%
                                                                               South-Ethiopia (Silti);                                                               Mean lesion duration:         10--30 sec per lesion                             Dropout: 14 (13.6%)                SSG: 89.5%
                                                                               11/2008-6/2009                                                                        8.5 months                    per visit)                                                                           [Cure (M3)]{.ul}: ulcers:
                                                                               LCL and MCL cases (n = 14)                                                            Mean age 19.6 years           SSG 20 mg/kg/day for 30          20               Cure: 17 (85.0%)                   complete scarring
                                                                               (active & passive case                                                                Male 14/20                    days IM---FU?                                     Non-response: 2 (10.0%)            Nodules: flattening
                                                                               finding)                                                                              Mean lesion duration:         (SSG if lesions: \> 3; or                         Dropout: 1 (5.0%)                  no inflammation
                                                                                                                                                                     13.1 months                   esthetically sensitive                                                               
                                                                                                                                                                                                   areas; or MCL)                                                                       
  \[[@pntd.0004495.ref005]\]                                                   Case series presented                                                                 Total 559 cases               Liquid nitrogen                  559              340 discharged cured               Partly overlapping with
                                                                               at consultative meeting                                                               341 male, 218 female          Duration variable                                 114 still on treatment             record above \[[@pntd.0004495.ref046]\]
                                                                               ALERT/AHRI                                                                            Age range 2--70 years         4--12 weeks up to \>                              105 interrupted                    
                                                                               Addis Abeba, 2001--2006                                                               79% lesion in face            60 weeks                                          (16 failing cases found            
                                                                               Confirmed CL cases                                                                    79% LCL, 4% multiple                                                            with other pathology)              
                                                                               Unclear about                                                                         CL; 17% MCL                                                                                                        
                                                                               species identification                                                                                                                                                                                   
  \[[@pntd.0004495.ref047]\]                                                   Case series, Kenya---LCL                                                              Male adults                   SSG 18--20 mg/kg IV twice        3                All patients improved and          No severe toxicity
                                                                               1981--1982                                                                            Age: 18, 21, 22 years         daily 30 days                                     parasite negative during           (mainly thrombosis and
                                                                               Cases unresponsive                                                                    Lesion duration 5, 7,                                                           treatment                          transient ECG and liver
                                                                               to SSG                                                                                9 months                                                                        All clinically cured (by           test abnormalities)
                                                                               Species identification in                                                                                                                                             M2-M6; one relapse by              
                                                                               One                                                                                                                                                                   1 year; improved with              
                                                                                                                                                                                                                                                     heat therapy                       
  \[[@pntd.0004495.ref048]\]                                                   Case report                                                                           Male, 29 years                SSG 20 mg/kg                                      Partial clinical response          1987: LCL cured after
                                                                               Addis Ababa, 1993                                                                     Original lesion               30 days                                           EOT; cured at M8                   SSG 30d;
                                                                               Recurrence of LCL                                                                     treated and cured                                                               Parasitological failure            Recurrence (1991): no effect
                                                                               due to AIDS                                                                           in 1987                                                                         (no change)                        effect of SSG
  **Main focus pentamidine**                                                                                                                                                                                                        of SSG 30 days                                      
  \[[@pntd.0004495.ref049]\]                                                   Case series                                                                           6 males, 2 females            Pentamidine (no details)         2                DCL: both "responded               2 LCL & 1 lupoid CL Not
                                                                               DCL (2)/LCL(6)                                                                        Age range 12--30 years                                                          well"                              not parasitologically
                                                                               combined with                                                                                                                                        1                CL (lupoid): "responded            Confirmed
                                                                               leprosy;                                                                                                                                                              well"                              7/8 lepra cases treated
                                                                               Addis Abeba, Ethiopia                                                                                                                                4                LCL: all "responded well"          (with dapsone)
                                                                               1965--67; 1974--76                                                                                                  Cycloguanil paomate              1                No info                            Outcome: "responded
                                                                               No species identification                                                                                                                                                                                well"; relapse in 1 LCL
  \[[@pntd.0004495.ref050]\]                                                   Case series,                                                                          Details lacking               Pentamidine (Lomidine) IM                         General comments:                  Despite dramatic
                                                                               20 complicated CL cases,                                                              No sex predominance           +/- 1 cc/10 kg every                              "Antimonials ineffective           improvement with,
                                                                               Ethiopia; 1965                                                                        Onset: age 4--12 years        2 d for 7 doses                                   (SSG 10 cc IM 17 days)"            recrudescence typically
                                                                               No species identification                                                             except one 57 years                                                             Pentamidine: "rapid                seen after pentamidine;
                                                                                                                                                                                                                                                     diminution of lesions"             All parasitologicallly
                                                                                                                                                                                                                                                                                        confirmed?
  \[[@pntd.0004495.ref051]\]                                                   Case series, MCL (4)                                                                  3 males, one female           Pentamidine 150 mg IM            2                Pentamidine: "very                 Antimonials used in 2
                                                                               Ethiopia, 1978                                                                        Age range 15--49 years        twice weekly for 8 weeks                          good response"                     Cases since no
                                                                               No species identification                                                                                           MA (Glucantime)                  2                MA: "no response"                  pentamidine vailable
                                                                                                                                                                                                   no details                                                                           
  \[[@pntd.0004495.ref052]\]                                                   Case series; LCL, DCL                                                                 104 pts; 40 females           Pentamidine mesylate                              49 LCL and all 6 DCL               55 pts treated, 20 with
                                                                               ALERT, Ethiopia                                                                       64 males                      (Lomidil) 2--4 mg/kg IM                           were treated                       severe toxicity;
                                                                               5/1981-4/1983                                                                         74% age 10--39                Alternate days                                    No efficacy data on LCL            15 withdrawn PM
                                                                               Species identification in part                                                        98 LCL, 6 DCL                 Duration not given                                DCL: All clinically                (severe nausea, vomiting,
                                                                               20                                                                                    DCL: mean duration                                                              improved at discharge              hypoglycaemia)
                                                                                                                                                                     5 years                                                                         3 still smear(+)                   3 diabetes mellitus; 1atient
  **Various**                                                                                                                                                                                                                                                                           
  \[[@pntd.0004495.ref053]\]                                                   Case series, Addis Abeba,                                                             2 females, 3 males            Metronidazole 3x500 mg 4--8      5                No clinical or histological        Remission after
                                                                               Ethiopia, 1978; MCL --                                                                                              Weeks                                             Changes                            treatment with
                                                                               parasitologically                                                                                                                                                                                        Pentamidine
                                                                               confirmed;                                                                                                                                                                                               Isethionate
                                                                               No species identification                                                                                                                                                                                No serious side effects
  \[[@pntd.0004495.ref054]\]                                                   Case series; LCL,                                                                     No details                    Cycloguanil pamoate (CI-         30               20 pts were reviewed at            Not all cases
                                                                               Wollega province                                                                                                    501; Camolar)                                     FU: improved (2); no               parasitologically
                                                                               Ethiopia, 1968                                                                                                      2x2.5 ml IM (2x 350 mg =                          change (8); ambiguous (3)          confirmed; Pts that
                                                                               No species identification                                                                                           twice the dose for                                ie both signs of                   improved had not
                                                                                                                                                                                                   for malaria treatment)                            worsening/improve                  been parasitologically
                                                                                                                                                                                                   lower for children; repeated                      ment; worsening (7)                confirmed
                                                                                                                                                                                                   at 6 weeks in 10 pts                                                                 
  \[[@pntd.0004495.ref055]\]                                                   Case report, LCL case                                                                 51 year old non,              Ketoconazole dose of 200         1                EOT: lesion 50%                    Minimal response with 4
                                                                               having lived in Tigray                                                                lesion duration: 27           mg b.i.d. for 4 weeks                             Reduction                          weeks application of
                                                                               region, Ethiopia                                                                      Months                                                                          By 2.5 months after                Pentamidine
                                                                               Lesion onset 1982,                                                                                                                                                    treatment: cure/lesion             dimethylsulfoxide gel
                                                                               Ketoconazole given 1984                                                                                                                                               healed                             No relapse at 12M
                                                                               No species identification                                                                                                                                                                                
  **Ethiopian/Eritrean migrants or travelers\[**[@pntd.0004495.ref054]**\]**                                                                                                                                                                                                            
  \[[@pntd.0004495.ref056]\]                                                   Case report                                                                           Two children (both            Ointment containing 15%          1                All parasitologically cured        Two developed allergic
                                                                               LCL in Ethiopian patients                                                             female), one male             paromomycin sulphate and                          at ten days                        contact dermatitis
                                                                               migrated to Israel, 1987                                                              One case first                12% methylbenzethonium                            All clinically cured but (end of   
                                                                               Longstanding LCL (2                                                                   treated with keto             chloride in white soft                            treatment extended in              
                                                                               years)                                                                                conazole 50mg/d               paraffin---applied twice                          two (10--30 days)                  
                                                                                                                                                                     for 4 weeks                   daily for 10 days                                 since at day 10 no clinical        
                                                                                                                                                                     without success                                                                 improvement                        
  \[[@pntd.0004495.ref057]\]                                                   Case report, LCL                                                                      No details                    Miltefosine---No details         1                Clinically cured                   CL probably
                                                                                                                                                                                                                                                                                        acquired in Egypt
  \[[@pntd.0004495.ref058]\]                                                   Case report                                                                           38-year old,                  Liposomal amphotericin B         1                Clinically improved by 3           On infliximab,
                                                                               LCL in Eritrean man                                                                   Immunosuppressed              60 mg/kg body weight in                           weeks; clinically cured at         methotrexate,
                                                                               travelled to Germany                                                                  male patient                  doses of 200 mg/day for 2                         12 month follow-up visit           and prednisolone for
                                                                                                                                                                     6x5 cm facial lesion          2 days (2.5--3 mg/kg/d x                                                             rheumatoid arthritis
                                                                                                                                                                                                   22); total dose 4.4 gram                                                             

^a^If the study period is not given, the year of publication is represented; cases parasitologicallly confirmed unless specified otherwise; species confirmation done (*L aethiopica*) unless specified otherwise

ALERT: All Africa Leprosy Rehabilitation and Training Center; AHRI: Armauer Hansen Research Institute; DCL: diffuse cutaneous leishmaniasis; EOT: end of treatment; IM: intramuscular; INH: isoniazid; LCL: localised cutaneous leishmaniasis; LST: Leishmania skin test; MA: meglumine antimonite; PO: per os; 1M FU: one month follow up; SSG: sodium stibugluconate

Two prospective studies including outcomes with antimonials and/or cryotherapy were found. In a study from Tigray, clinical non-response was observed in 23 (15%) of the 154 treated (intralesional or systemic SSG). Failure rates were particularly high in MCL and DCL cases and all of the HIV cases relapsed. In a study in Southern Ethiopia with a main focus on cryotherapy, 20 cases not qualifying for cryotherapy were treated with systemic SSG but two (10%) did not respond clinically. This study mainly included LCL, and most of these were identified during active case finding, which could possibly have led to earlier CL diagnosis. This study is also the only formal evaluation of cryotherapy in Ethiopia, showing cure in 81% of cases. A large case series of cryotherapy from the same centre demonstrated cure rates of 60--70% \[[@pntd.0004495.ref005]\]. In Kenya, three cases unresponsive to standard SSG treatment were successfully treated with a high dose (18--20 mg/kg twice daily for 30 days). *In vitro* data generally suggested a low susceptibility of *L aethiopica* to antimonials ([Table 5](#pntd.0004495.t005){ref-type="table"}).

10.1371/journal.pntd.0004495.t005

###### Drug susceptibility studies on *L. aethiopica*.

![](pntd.0004495.t005){#pntd.0004495.t005g}

  Ref                          Assay; parasite strains                                                                                          IC50 or ED50                                                     Comments
  ---------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  \[[@pntd.0004495.ref018]\]   Amastigote-macrophage *in vitro* model---CD1 mouse                                                               IC50 (μg/ml ± SD)                                                MF: maximal efficacy against all three forms; followed by ampho against LCL; by PM against DCL/ML;
                               derived PEMs                                                                                                     \- Ampho: 0.16 ± 0.18                                            DCL/ML generally less sensitive
                               Patient strains:                                                                                                 \- MF: 5.88 ± 4.79                                               
                               LCL: 8; MCL: 9; DCL: 7                                                                                           \- SSG: 10.23 ± 8.12                                             
                                                                                                                                                \- Paromo: 13.63 ± 18.74                                         
  \[[@pntd.0004495.ref020]\]   Human leukemia monocyte cell line THP-1                                                                          ED50:                                                            *L*. *aethiopica* less sensitive to SSG than *L donovani*
                               MHOM/ET/72/L100 strain                                                                                           \- SSG: 25.3 μg SbV/ml;                                          
                                                                                                                                                \- PM: 0.6 μM                                                    
                                                                                                                                                \- Paromo: 6.4 μM                                                
  \[[@pntd.0004495.ref019]\]   Promastigote assay; Amastigote-macrophage assay (peritoneal CD1 mouse macrophages)                               Promastigote (ED50-μM)                                           Ampho most active (submicromolar concentration)
                               MHOM/ET/84/KH strain                                                                                             \- MF: 1.16--2.76                                                Tested in parallel: L Major generally least susceptible, *L donovani* most susceptible
                                                                                                                                                \- Edelfosine: 0.62--1.28                                        
                                                                                                                                                \- Ampho: 0.11--0.24                                             
                                                                                                                                                Amastigote (ED50-μM)                                             
                                                                                                                                                \- MF: 2.63--4.92                                                
                                                                                                                                                \- Edelfosine: 1.15--2.92                                        
                                                                                                                                                \- Ampho: 0.04--0.07                                             
  \[[@pntd.0004495.ref021]\]   THP-1 monocyte cell line                                                                                         1\) ED50: 4.0 μg/mL (pre-treatment); 21.9 μg/mL (at relapse);    ED50 for SSG high: 78.2 μg Sb/ml (pt 1); 55.0 μg (pt 2)
                               Patient strains (DCL-Ethiopia); Two patients (1,2) treated with PM and subsequent relapse, improving on PM/SSG   2\) ED50: 7.1 μg/mL (pre-treatment),: 21.3 μg/mL(at relapse)--   Sb/ml synergism with SSG in both patients
                               Patient 3 treated with PM/SSG                                                                                    3\) ED50: 15.0 μg/mL (pre-treatment)                             

ampho: amphotericin B deoxychelate; DCL: diffuse cutaneous leishmaniasis (CL); ED50: effective dose 50; IC50: inhibitory dose 50; LCL: localized CL; MCL mucocutaneous leishmaniasis; MF: miltefosine;; Paromo: paromomycin; PEM: Peritoneal exudate macrophages; PM: pentamidine; SSG: sodium stibogluconate; Sb: pentavalent antimonial.

A number of (often older) studies reported pentamidine---in contrast to antimonials---to be effective against CL (including MCL). However, this were typically case series, reporting on patients from routine clinical practice and without standardized outcome reporting. Pentamidine also appeared effective in the above mentioned clinical trial and in the complicated CL cases (CL relapse not responding to SSG including MCL) in the prospective study from Tigray \[[@pntd.0004495.ref007]\]. We identified one case study of LCL treated with ketoconazole, with 50% lesion reduction at the end of treatment and cure 2.5 months later.

Several small studies reported on treatment in countries outside Ethiopia. Paromomycin ointment was highly effective in three Ethiopians treated in Israel. As to miltefosine, one case of successful treatment was reported in Germany. Of interest, miltefosine has been successfully used in more than 50 CL cases due to *L aethiopica* in Addis Ababa, but the findings have not been published (personal communication, Asrat Hailu). Liposomal amphotericin B was found effective in one immunosuppressed Eritrean patient treated in Germany.

Four studies included MCL patients. Metronidazole was ineffective in five cases of MCL. Antimonials were usually not found effective, but better outcomes were generally observed with pentamidine.

The available *in vitro* data relating to these drugs suggest a good susceptibility of *L aethiopica* to miltefosine, paromomycin, pentamidine and amphotericin B ([Table 5](#pntd.0004495.t005){ref-type="table"}). The most recent study by Utaile *et al* was conducted in Ethiopia using strains isolated from patients \[[@pntd.0004495.ref018]\]. Parasite susceptibility was highest for AmBisome (in the sub-micromolar range), followed by miltefosine with an IC~50~ of 5.88 μg/ml. Efficacy of miltefosine against visceral leishmaniasis and other CL-causing species was exerted in a similar low micromolar range. Miltefosine had the highest maximal efficacy against CL, MCL and DL. Paromomycin had the highest IC~50~ but had the second highest maximal efficacy against MCL and CL strains. Two other studies used reference strains. In the study by Escobar *at al*, amphotericin B was again active at low concentrations; the ED~50~ for miltefosine was less than 5 μM \[[@pntd.0004495.ref019]\]. In a third study, pentamidine had the lowest ED~50~ (0.6 μM), followed by paromomycin (ED~50~ 6.4 μM) \[[@pntd.0004495.ref020]\]. In another study, paromomycin was evaluated against three strains, with ED~50~ of 4.0--15.0 μg/ml before treatment \[[@pntd.0004495.ref021]\]. Antimonials were only active at high concentrations, but exerted synergism with PM which correlated with the clinical response.

Clinical studies on DCL treatment {#sec008}
---------------------------------

As to treatment with pentamidine, we found data on 62 patients in a total of ten studies ([Table 6](#pntd.0004495.t006){ref-type="table"}). The largest group of patients stems from pioneering work done by Bryceson and colleagues in the late sixties, reporting on 31 patients treated with varying regimens of pentamidine. Of 24 patients receiving pentamidine daily or every other day in the study by Bryceson, all improved during treatment although none was cured. However, frequent pentamidine administration was associated with substantial toxicity. With less frequent administration, safety was improved at the expense of efficacy. An additional four cases were reported in four other studies, all showing clinical improvement.

10.1371/journal.pntd.0004495.t006

###### Clinical studies specifically focused on diffuse cutaneous leishmaniasis due to *L. aethiopica*.

![](pntd.0004495.t006){#pntd.0004495.t006g}

  Ref                                                 Study design; country; year; study population[^a^](#t006fn001){ref-type="table-fn"}   Patient characteristics   Drug/Intervention                                        N    Efficacy                                   Comments
  --------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------- -------------------------------------------------------- ---- ------------------------------------------ ---------------------------
  \[[@pntd.0004495.ref059]\]                          Case series; DCL                                                                      Female, 28 years          Pentamidine                                              1    Clinical, histological                     No info on toxicity
                                                      Ethiopia; 1982                                                                        DCL for 2 years           dimethane sulphonate                                          and parasitological                        Male pt had been
                                                                                                                                            Male, 35 years,           200 mg (Lomidine) daily                                       improvement by EOT                         treated with
                                                                                                                                            DCL for 10 year           IM for two weeks                                              (no "cure")                                pentamidine before
                                                                                                                                                                                                                                                                               but had relapsed
  \[[@pntd.0004495.ref060]\]                          Case series; DCL                                                                                                Pentamidine dimethansulphonate 4 mg/kg                   31   31 improved (7 cured)                      Cure: clinic-
                                                      Ethiopia; 1970                                                                                                  (Lomidine)                                                                                               parasitological
                                                      No species identification                                                                                       \- Daily or alternative days (4--23 doses); TD 1--3.4g   24   24 improved (0 cured)                      resolution; Improved:
                                                                                                                                                                                                                                    13 relapse                                 clinical improvement;
                                                                                                                                                                      \- Weekly (4--21 weeks); TD 0.7--2.4g                    12   11 improved (1 cured)                      Relapse common; Most
                                                                                                                                                                      \- Every two weeks (2-10w)                               9    6 improved (2 cured)                       toxicity with PM &
                                                                                                                                                                      \- Monthly (5--6 months)                                 5    3 relapses; 2 lost                         amphotericin B; dose-
                                                                                                                                                                      Pentostam: 10--20 mg/kg 5--30 days, TD 3--17 gr          17   0 improved 0                               limiting toxicity with
                                                                                                                                                                      Glucantime: 10--21 days; 12 mg/kg 10--21 days (TD        8    4 improved                                 frequently doses PM
                                                                                                                                                                      3--12.6 gr)                                                                                              
                                                                                                                                                                      SSG + pentamidine                                        16   12 improved (4 cured)                      Other drugs tested (no
                                                                                                                                                                      (for relapse after SSG)                                       6 relapsed                                 convincing effects):
                                                                                                                                                                      alternating 10 doses                                                                                     high dose antimalarials;
                                                                                                                                                                      each (2--8 weeks)                                                                                        astiban macrocylon,
                                                                                                                                                                      Amphotericin B 1 mg/kg on alternating days (29--48       4    4 improved 4 (1 cured)                     Griseofulvine
                                                                                                                                                                      mg/kg TD over 3--5 months)                                                                               
  \[[@pntd.0004495.ref061],[@pntd.0004495.ref062]\]   Case report                                                                           40 year old female        PM isethionate 200 mg IM every                                Marked reduction in reduclinimprovement,   Mention \>100 CL cases
                                                      DCL relapse after PM                                                                  DCL since 25 years        every 2 d for one month                                       parasite load; no DM                       PM treated 1974--79
                                                      Previously transient DM                                                               Non-response to                                                                         Subsequent relapse                         PM isethionate 200 mg IM
                                                      with Lomisil (pentamidine                                                             MA, metronidazole                                                                       treated with Lomisil:                      daily 15 days: no DM
                                                      mesylate)                                                                             dapsone,                                                                                developed DM                               Lomisil period 1979--80
                                                      AHRI, Ethiopia; 1978                                                                  Chloroquine                                                                                                                        DM in 2/30 in 2 year
                                                                                                                                            Clofazimine                                                                                                                        
  \[[@pntd.0004495.ref021]\]                          Case series, DCL                                                                      Male (2)                  Paromo 14 mg/kg 60 days                                  2    EOT complete clinico-                      Relapse after 1 and 3
                                                      Addis Ababa,                                                                                                    (2 cases of DCL)                                              parasitological resolution                 months; subsequently
                                                      Ethiopia, 1990--1992                                                                                            (reduced to 12 mg/kg                                                                                     Treated with paramo +
                                                      No species identification                                                                                       3x/weeks in one pt due to                                                                                SSG
                                                                                                                                                                      renal dysfunction                                                                                        
                                                                                                                                            Male (2); female (1)      Paromo 14 mg/kg + SSG                                    3    EOT complete clinico-                      Relapse free at 17, 2 and
                                                                                                                                                                      10 mg/kg 2 months-                                            parasitological resolution                 21 months; Audiograms
                                                                                                                                                                      beyond parasitological cure                                                                              normal
                                                                                                                                                                      (6--9 months; 2 patients                                                                                 PM dose reduction in
                                                                                                                                                                      relapsing after paromo (see                                                                              one patient for renal
                                                                                                                                                                      above) + 1 new patient                                                                                   Dysfunction
  \[[@pntd.0004495.ref063]\]                          Case series, DCL                                                                      Three (no details)        Chlorpromazine 2%                                        3    All became smear neg                       No long term outcome
                                                      Addis Ababa,                                                                                                    ointment for one month                                        Inflammation dis-                          All three confirmed
                                                      Ethiopia; 1983                                                                                                                                                                appeared (3); regression                   parasitologically
                                                      No species identification                                                                                                                                                     of affected area (1)                       
  \[[@pntd.0004495.ref053]\]                          Case series, DCL                                                                      Two (no details)          Metronidazole---no details                               2    Initial clinical                           No complete remission
                                                      Addis Ababa; 1978                                                                                               Given                                                         improvement;                               
                                                      No species identification                                                                                                                                                     histologically confirmed: 1                
                                                                                                                                                                                                                                    1                                          
  \[[@pntd.0004495.ref064]\]                          Case series, DCL                                                                      Atypical DCL (n = 2);     MA 28 days IM                                            2    Clinical improvement                       One case received
                                                      Mekele; 2013                                                                          alike borderline-                                                                       EOT                                        a second treatment
                                                      No species identification                                                             tuberculoid leprosy                                                                                                                course for consolidation
                                                                                                                                            Males (18, 20 years)                                                                                                               

^a^If the study period is not given, the year of publication is represented; cases parasitologicallly confirmed unless specified otherwise; species confirmation done (*L aethiopica*) unless specified otherwise

ALERT: All Africa Leprosy Rehabilitation and Training Center; AHRI: Armauer Hansen Research Institute; DCL: diffuse cutaneous leishmaniasis; EOT: end of treatment; IM: intramuscular; INH: isoniazid; LCL: localised cutaneous leishmaniasis; LST: Leishmania skin test; MA: meglumine antimonite; PO: per os; 1M FU: one month follow up; SSG: sodium stibugluconate

Outcomes with systemic antimonials were reported in 38 cases, of which only nine demonstrated clinical response. A prolonged course of paromomycin was successful in treating two cases of DCL, although both relapsed \[[@pntd.0004495.ref021]\]. Three patients (including these two relapse cases) have been successfully treated with an extended course of paromomycin combined with SSG. Good susceptibility to paromomycin, poor susceptibility to antimonials but synergism between SSG and paromomycin could be demonstrated *in vitro* \[[@pntd.0004495.ref021]\]. In the study by Bryceson, sixteen individuals were treated with antimonials and pentamidine in combination. Twelve improved during treatment, seven were declared cured. In the same study, all four cases treated with conventional amphotericin B treatment improved, but toxicity was substantial.

Metronidazole was tried in two patients, who displayed clinical improvement. As mentioned above, itraconazole was generally not found to be effective. Chlorpromazine ointment displayed some effect in a small case series, reported over 30 years ago.

Discussion {#sec009}
==========

The evidence base for treatment of CL due to *L aethiopica* remains extremely poor. Most studies were conducted decades ago, including often involving a few patients, lacking appropriate control groups and usually not employing a well-defined and rigid methodology. Outcome measures varied widely across the different reports. In drug susceptibility studies, pentamidine, paromomycin, amphotericin and miltefosine looked most promising. Antimonials were only effective *in vitro* at relatively high doses. Some studies supported the efficacy of antimonials against LCL, others reported on the poor efficacy. Both the national and WHO recommend topical or systemic administration of antimonials for LCL treatment in Ethiopia ([Table 7](#pntd.0004495.t007){ref-type="table"}) and, despite the lack of a good evidence base, antimonials remain the most widely available anti-leishmanial drug in Ethiopia. Given the common and sometimes severe toxicity of antimonials, better defining its efficacy against CL in clinical trials is urgently needed.

10.1371/journal.pntd.0004495.t007

###### Ethiopian and WHO guidelines for treatment of cutaneous leishmaniasis in Ethiopia.

![](pntd.0004495.t007){#pntd.0004495.t007g}

                     National guidelines                                                 WHO guidelines
  ------------------ ------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Local Therapy      \- Intra-lesion SSG weekly for four to six weeks                    Several options but indicating limited evidence base
                     \- Cryotherapy                                                      \- Cryotherapy or intra-lesional
                     \- Curetage[^a^](#t007fn002){ref-type="table-fn"}                   SSG (alone or combined)
                     \- Heat therapy[^a^](#t007fn002){ref-type="table-fn"}               \- Thermotherapy
                     \- Topical ointment[^a^](#t007fn002){ref-type="table-fn"}           \- Topical ointment
  Systemic therapy   \- Paromomycin 14--15mg (sulphate)/ kg for 20--30 days              \- 20 mg of Sb5+/kg/d IM or IV for 28 days
                     \- 20mg Sb5+/kg/day IM or IV for 4--8 weeks                         
                     \- Miltefosine[^a^](#t007fn002){ref-type="table-fn"}                
                     \- Liposomal amphotericin B[^a^](#t007fn002){ref-type="table-fn"}   
  Diffuse CL         \- Paromomycin 15mg/kg + SSG 10mg/kg                                \- 20 mg of Sb5+/kg/d IM or IV for 28 days + Paromomycin 15 mg/kg/day IM for 60 days or longer (C)
                                                                                         \- Pentamidine isethionate 3--4 mg/kg/d IV once or twice weekly (up to 4 months) (C)

Level of Evidence (C): Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees

^a^ guideline stipulates these have not yet been used for CL in Ethiopia

CL: cutaneous leishmaniasis; IM: intramuscular; IV: intravenous; SSG: sodium stibugluconate

Sb5+: pentavalent antimonial

The national guidelines recommend intramuscular paromomycin as the preferential LCL first line treatment. This is backed-up by *in vitro* data, although clinical evidence is very scarce with only a small case series on DCL and no reports on LCL caused by *L aethiopica*. Its good safety profile and availability in Ethiopia argue for its evaluation in clinical trials. At a dose of 12--18 mg/kg/day for 14 days, cure rates of over 90% were obtained in Brazil \[[@pntd.0004495.ref022]\], but only 50--60% in Colombia and in Belize \[[@pntd.0004495.ref023],[@pntd.0004495.ref024]\].

Clinical efficacy of miltefosine has varied globally according to the etiological species and geographical area. In drug susceptibility testing, miltefosine looked promising against *L aethiopia*, warranting clinical studies. Miltefosine is now increasingly available in East-Africa for VL treatment, creating opportunities for CL as well. Few studies are available on the use of miltefosine against other species causing Old World CL. In one trial from Iran, miltefosine was found as effective as intralesional antimonials against CL caused by *L major* \[[@pntd.0004495.ref025]\]. As to New World LCL, the efficacy of miltefosine varied across regions and/or species \[[@pntd.0004495.ref026]\].

Although pentamidine appeared effective in antimonial-resistant complicated CL, given its safety profile, it would probably only be considered as second line treatment for LCL. Given their ready availability in resource-limited settings (often via HIV programs), the efficacy of drugs such as ketoconazole and fluconazole merit further exploration.

Data on the efficacy of topical and physical therapies are very limited. Only cryotherapy and intralesional antimonials have to some extent been evaluated against CL in Ethiopia. Other topical (e.g., paromomycin) and physical therapies might be worth exploring, particular if easy to administer and if implementable in remote settings with limited well-trained health care staff. Recent findings with thermotherapy from Peru are modestly encouraging \[[@pntd.0004495.ref027]\]. Topical application of amphotericin B is currently in early clinical evaluation by the Drugs for Neglected Diseases initiative (DND*i*) against *L braziliensis* and *L tropica* ([www.dndi.org](http://www.dndi.org)). If promising, this should be expanded to *L aethiopica*.

Treatment of DCL has been notoriously difficult. While there have been only a few studies on pentamidine, available data seem to indicate a relatively good efficacy, although relapse was commonly observed after pentamidine discontinuation. While toxicity has been a critical concern issue with daily administration (for instance as treatment for human African trypanosomiasis), less frequent administration (e.g., every other day) appeared to be well tolerated while still effective. The WHO recommendations also include pentamidine for DCL treatment. Nevertheless, cumulative toxicity remains a concern, especially as to the risk of diabetes \[[@pntd.0004495.ref028],[@pntd.0004495.ref029]\]. Eight cases of diabetes have been reported from Ethiopia, presumably related to pentamidine use, also in cases that received less frequent administration. However, it is important to note that in the earlier studies pentamidine mesylate (Lomidine) was used, labelled according to the base-moiety (120 mg base per ampoule) with a recommended dose of 4 mg base/kg body weight. Currently, pentamidine isethionate (Pentacarinat or Pentam) is used, labelled according to the amount of salt in the preparation (300 mg salt per ampoule) with a recommended dose of 4 mg of salt/kg. In practical terms, this means that earlier studies employed a higher dose (7 mg of salt/kg) than currently being advised by the company (4 mg of salt/kg) \[[@pntd.0004495.ref030]\]. While possibly leading to improved tolerance, it is unclear to what extent efficacy would be compromised. Nevertheless, the potential risk of diabetes and other adverse effects requires close clinical and laboratory monitoring, restricting its' use to better established health facilities.

Both the WHO and national guidelines include the combination of paromomycin and antimonials for DCL treatment, albeit with different dosing of the antimonials and acknowledging the limited evidence base. This combination now constitutes the first line VL treatment in VL endemic east African countries, which would facilitate its implementation if found effective. Nevertheless, a daily parenteral treatment regimen of at least two months remains cumbersome and can only be seen as a short-term solution. Paromomycin and miltefosine in combination would also be worth evaluating. Miltefosine was found effective against DCL in a small study conducted in Venezuela, with most cases caused by *Leishmania amazonensis*, although all but one subsequently relapsed \[[@pntd.0004495.ref031]\]. This combination (given for ten days) has been found safe and effective against visceral leishmaniasis in India \[[@pntd.0004495.ref032]\].

Even if more potent drugs for DCL would be identified, most cases are likely to relapse after treatment discontinuation, unless the underlying immunosuppression can be altered. This provides the rationale for complementary approaches such as adjuvant immunotherapy. Effective treatment of DCL will most likely require adjuvant strategies such as immunotherapy to consolidate the treatment response. Therapeutic vaccination with first generation vaccines---has been found effective against DCL and ML in the New World \[[@pntd.0004495.ref033],[@pntd.0004495.ref034]\], but has not yet been explored in Ethiopia. Moreover, second generation vaccines have been developed \[[@pntd.0004495.ref035]\], which looked promising in phase I studies against New World CL and ML \[[@pntd.0004495.ref036],[@pntd.0004495.ref037]\]. DNDi ([www.dndi.org](http://www.dndi.org)) is currently exploring the use of CpG-DNA \[[@pntd.0004495.ref038]--[@pntd.0004495.ref042]\] for CL due to *L braziliensis* and *L tropica*. An interesting approach could combine chemotherapy with therapeutic vaccination with a second generation vaccine and/or CpG-DNA against the different forms of CL.

Trials should probably initially focus on LCL and possibly MCL, since this is the predominant clinical presentation. However, efforts should also be made to provide treatment to more complicated manifestations within clinical trials such as DCL (e.g., via a compassionate use protocol in a well-documented case series). Given the lack of quality data on any of the available treatments, several potentially interesting interventions should be evaluated in future clinical trials, with the most promising ones taken further in more extensive evaluations. Adaptive clinical trial designs have been increasingly used in NTDs, since these have the potential to more quickly and efficiently weed out ineffective regimens across the different intervention arms \[[@pntd.0004495.ref043],[@pntd.0004495.ref044]\]. For non-complicated LCL, various topical or physical therapies should be evaluated.

As to systemic treatment for complicated CL, interventions to be prioritized for evaluation include paromomycin, miltefosine and antimonials (possibly combined with paromomycin). While the higher cost of liposomal amphotericin B is an obvious disadvantage, price reductions (e.g. via generics) remain possible and the drug is increasingly available in VL endemic countries \[[@pntd.0004495.ref045]\].

In conclusion, the evidence-base for treatment of CL due to *L aethiopica* is extremely limited, warranting prospective clinical studies. While antimonials might for the time being remain the cornerstone of CL treatment, not in the least because of their availability and clinical experience within Ethiopia, their efficacy and safety in CL should be better defined. Most importantly, alternative first line treatments should be explored, preferably topically or to be taken orally. As to DCL, the options appear limited. Pentamidine appears most promising, but toxicity is an issue. High quality trials on CL due to L aethiopica are urgently needed. A good scenario would be several options in parallel using adaptive designs/group sequential methods to discontinue the arms with ineffective drugs.

Supporting Information {#sec010}
======================

###### PRISMA Checklist.

(DOC)

###### 

Click here for additional data file.

[^1]: The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: JvG ED. Performed the experiments: JvG ED. Analyzed the data: JvG ED EG AH AA AMB. Wrote the paper: JvG ED AA AH EG AMB.
